Last updated on November 2019
Lynparza Breast Cancer Clinical Experience Investigation
Brief description of study
To characterise the development of ADRs of bone marrow depression in patients under actual post-marketing use.
Detailed Study Description
To characterise the development of adverse drug reactions (ADRs) of bone marrow depression in patients with unresectable or recurrent BRCA mutated HER2 negative breast cancer who have previously received anticancer chemotherapy under actual post-marketing use.
Clinical Study Identifier: NCT03590938